Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Receptors, Purinergic P2Y12"" wg kryterium: Temat


Tytuł :
Loss of P2Y12 Has Behavioral Effects in the Adult Mouse.
Autorzy :
Lowery RL; Center for Visual Science, Department of Neuroscience, University of Rochester, Rochester, NY 14642, USA.
Mendes MS; Center for Visual Science, Department of Neuroscience, University of Rochester, Rochester, NY 14642, USA.; Department of Biology, Stanford University, Stanford, CA 94305, USA.
Sanders BT; Center for Visual Science, Department of Neuroscience, University of Rochester, Rochester, NY 14642, USA.
Murphy AJ; Center for Visual Science, Department of Neuroscience, University of Rochester, Rochester, NY 14642, USA.
Whitelaw BS; Center for Visual Science, Department of Neuroscience, University of Rochester, Rochester, NY 14642, USA.
Lamantia CE; Center for Visual Science, Department of Neuroscience, University of Rochester, Rochester, NY 14642, USA.
Majewska AK; Center for Visual Science, Department of Neuroscience, University of Rochester, Rochester, NY 14642, USA.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 13; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 13.
Typ publikacji :
Journal Article
MeSH Terms :
Behavior, Animal*
Neuronal Plasticity*
Anxiety/*metabolism
Brain/*metabolism
Receptors, Purinergic P2Y12/*deficiency
Synapses/*metabolism
Animals ; Anxiety/genetics ; Anxiety/pathology ; Brain/pathology ; Memory ; Mice ; Mice, Knockout ; Receptors, Purinergic P2Y12/metabolism ; Synapses/genetics ; Synapses/pathology
Czasopismo naukowe
Tytuł :
Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y 1 and P2Y 12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor.
Autorzy :
Lei Y; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Zhang B; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Liu D; Shenyang Hinewy Pharmaceutical Technology Co., Ltd., 41 Liutang Road, Shenhe District, Shenyang 110016, China.
Zhao J; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Dai X; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Gao J; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Mao Q; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Feng Y; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Zhao J; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Lin F; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Duan Y; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Zhang Y; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Bao Z; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Yang Y; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Mou Y; Department of Pharmacology, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Wang S; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Dec 24; Vol. 63 (24), pp. 15752-15772. Date of Electronic Publication: 2020 Dec 12.
Typ publikacji :
Journal Article
MeSH Terms :
Enzyme Inhibitors/*chemistry
Platelet Aggregation Inhibitors/*chemistry
Purinergic P2Y Receptor Antagonists/*chemistry
Receptors, Purinergic P2Y1/*chemistry
Receptors, Purinergic P2Y12/*chemistry
Xanthine Oxidase/*antagonists & inhibitors
Animals ; Binding Sites ; Cytochrome P-450 Enzyme System/chemistry ; Cytochrome P-450 Enzyme System/metabolism ; Drug Stability ; Enzyme Inhibitors/metabolism ; Enzyme Inhibitors/pharmacology ; Half-Life ; Humans ; Imidazoles/chemistry ; Imidazoles/metabolism ; Imidazoles/pharmacology ; Mice ; Microsomes, Liver/metabolism ; Molecular Docking Simulation ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/metabolism ; Platelet Aggregation Inhibitors/pharmacology ; Purinergic P2Y Receptor Antagonists/metabolism ; Rats ; Receptors, Purinergic P2Y1/metabolism ; Receptors, Purinergic P2Y12/metabolism ; Structure-Activity Relationship ; Ticagrelor/pharmacology ; Xanthine Oxidase/metabolism
Czasopismo naukowe
Tytuł :
Inhibiting P2Y12 in Macrophages Induces Endoplasmic Reticulum Stress and Promotes an Anti-Tumoral Phenotype.
Autorzy :
Pavlović N; Medical Cell Biology, Uppsala University, 75123 Uppsala, Sweden.
Kopsida M; Medical Cell Biology, Uppsala University, 75123 Uppsala, Sweden.
Gerwins P; Medical Cell Biology, Uppsala University, 75123 Uppsala, Sweden.; Radiology, Uppsala University Hospital, 75237 Uppsala, Sweden.
Heindryckx F; Medical Cell Biology, Uppsala University, 75123 Uppsala, Sweden.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Oct 31; Vol. 21 (21). Date of Electronic Publication: 2020 Oct 31.
Typ publikacji :
Journal Article
MeSH Terms :
Endoplasmic Reticulum Stress/*drug effects
Liver Cirrhosis, Experimental/*prevention & control
Liver Neoplasms, Experimental/*prevention & control
Macrophages/*metabolism
Receptors, Purinergic P2Y12/*chemistry
Taurochenodeoxycholic Acid/*pharmacology
Ticagrelor/*pharmacology
Animals ; Cell Line, Tumor ; Cholagogues and Choleretics/pharmacology ; Humans ; Liver Cirrhosis, Experimental/metabolism ; Liver Cirrhosis, Experimental/pathology ; Liver Neoplasms, Experimental/metabolism ; Liver Neoplasms, Experimental/pathology ; Male ; Mice ; Mice, Inbred C57BL ; Purinergic P2Y Receptor Antagonists/pharmacology ; Receptors, Purinergic P2Y12/metabolism ; Unfolded Protein Response/drug effects
Czasopismo naukowe
Tytuł :
Utility of P2Y 12 Reactive Unit Assessment on Ticagrelor in Cerebral Aneurysms Treated with Intracranial Stenting and Flow Diversion: Cohort Study and Case Report From Two Neurovascular Centers.
Autorzy :
Bohan CO; Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA.
Wirtz MM; Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA.
Hendrix P; Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA; Department of Neurosurgery, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany.
Goren O; Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA.
Schirmer CM; Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA; Research Institute of Neurointervention, Paracelsus Medical University, Salzburg, Austria.
Islak C; Department of Neuroradiology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.
Grassi DM; Enterprise Pharmacy, Geisinger, Danville, Pennsylvania, USA.
Dalal S; Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA; Department of Radiology, Geisinger, Danville, Pennsylvania, USA.
Weiner G; Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA.
Griessenauer CJ; Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA; Research Institute of Neurointervention, Paracelsus Medical University, Salzburg, Austria. Electronic address: .
Pokaż więcej
Źródło :
World neurosurgery [World Neurosurg] 2020 Oct; Vol. 142, pp. e445-e452. Date of Electronic Publication: 2020 Jul 17.
Typ publikacji :
Case Reports; Journal Article; Multicenter Study
MeSH Terms :
Receptors, Purinergic P2Y12*
Intracranial Aneurysm/*drug therapy
Intracranial Aneurysm/*surgery
Purinergic P2Y Receptor Antagonists/*administration & dosage
Self Expandable Metallic Stents/*trends
Ticagrelor/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Follow-Up Studies ; Humans ; Intracranial Aneurysm/diagnostic imaging ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Potential and Limitations of the New P2Y12 Inhibitor, Cangrelor, in Preventing Heparin-Induced Platelet Aggregation During Cardiac Surgery: An In Vitro Study.
Autorzy :
Scala E; From the Department of Anesthesiology.; Division of Hematology, Department of Oncology and Central Hematology Laboratory, Department of Laboratory Medicine and Pathology, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois [CHUV]) and University of Lausanne (UNIL), Lausanne, Switzerland.
Gerschheimer C; Division of Hematology, Department of Oncology and Central Hematology Laboratory, Department of Laboratory Medicine and Pathology, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois [CHUV]) and University of Lausanne (UNIL), Lausanne, Switzerland.
Gomez FJ; Division of Hematology, Department of Oncology and Central Hematology Laboratory, Department of Laboratory Medicine and Pathology, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois [CHUV]) and University of Lausanne (UNIL), Lausanne, Switzerland.
Alberio L; Division of Hematology, Department of Oncology and Central Hematology Laboratory, Department of Laboratory Medicine and Pathology, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois [CHUV]) and University of Lausanne (UNIL), Lausanne, Switzerland.
Marcucci C; From the Department of Anesthesiology.
Pokaż więcej
Źródło :
Anesthesia and analgesia [Anesth Analg] 2020 Aug; Vol. 131 (2), pp. 622-630.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Receptors, Purinergic P2Y12*/blood
Adenosine Monophosphate/*analogs & derivatives
Anticoagulants/*adverse effects
Cardiac Surgical Procedures/*methods
Heparin/*adverse effects
Platelet Aggregation/*drug effects
Purinergic P2Y Receptor Antagonists/*pharmacology
Adenosine Monophosphate/blood ; Adenosine Monophosphate/pharmacology ; Anticoagulants/blood ; Cardiac Surgical Procedures/adverse effects ; Heparin/blood ; Humans ; Platelet Aggregation/physiology ; Purinergic P2Y Receptor Antagonists/blood
Czasopismo naukowe
Tytuł :
sLRP1 (Soluble Low-Density Lipoprotein Receptor-Related Protein 1): A Novel Biomarker for P2Y12 (P2Y Purinoceptor 12) Receptor Expression in Atherosclerotic Plaques.
Autorzy :
Chen J; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pi S; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yu C; Department of Ultrasound (C.Y.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Shi H; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu Y; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Guo X; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhou L; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Li Y; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
He H; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xia Y; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Mao L; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hu B; From the Department of Neurology (J.C., S.P., H.S., Y. Liu, X.G., L.Z., Y. Li, H.H., Y.X., L.M., B.H.), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pokaż więcej
Źródło :
Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2020 Jun; Vol. 40 (6), pp. e166-e179. Date of Electronic Publication: 2020 Apr 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression*
Biomarkers/*analysis
Low Density Lipoprotein Receptor-Related Protein-1/*analysis
Plaque, Atherosclerotic/*metabolism
Receptors, Purinergic P2Y12/*genetics
Actins/analysis ; Animals ; Apolipoproteins E/deficiency ; Apolipoproteins E/genetics ; Apolipoproteins E/physiology ; Clopidogrel/pharmacology ; Cyclic AMP/metabolism ; Cyclic AMP-Dependent Protein Kinases/metabolism ; Diet, High-Fat ; Gene Knockdown Techniques ; Low Density Lipoprotein Receptor-Related Protein-1/blood ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Muscle, Smooth, Vascular/chemistry ; Muscle, Smooth, Vascular/metabolism ; Plaque, Atherosclerotic/chemistry ; Purinergic P2Y Receptor Antagonists/pharmacology ; Receptors, Purinergic P2Y12/drug effects ; Receptors, Purinergic P2Y12/physiology ; Signal Transduction ; Sterol Regulatory Element Binding Protein 2/metabolism
Czasopismo naukowe
Tytuł :
P2Y 12 Inhibition beyond Thrombosis: Effects on Inflammation.
Autorzy :
Mansour A; Université de Paris, Innovative Therapies in Haemostasis, INSERM 1140, F-75006 Paris, France.; CHU de Rennes, Department of Anesthesiology Critical Care Medicine and Perioperative Medicine, F-35000 Rennes, France.; INSERM, CIC 1414 (Centre d'Investigation Clinique de Rennes), Université de Rennes, CHU de Rennes, F-35000 Rennes, France.
Bachelot-Loza C; Université de Paris, Innovative Therapies in Haemostasis, INSERM 1140, F-75006 Paris, France.
Nesseler N; CHU de Rennes, Department of Anesthesiology Critical Care Medicine and Perioperative Medicine, F-35000 Rennes, France.; INSERM, CIC 1414 (Centre d'Investigation Clinique de Rennes), Université de Rennes, CHU de Rennes, F-35000 Rennes, France.; INRA, INSERM, Institut NUMECAN-UMR_A 1341, Université de Rennes, CHU de Rennes, UMR_S 1241, F-35000 Rennes, France.
Gaussem P; Université de Paris, Innovative Therapies in Haemostasis, INSERM 1140, F-75006 Paris, France.; AP-HP, Hôpital Européen Georges Pompidou, Department of Biological Hematology, F-75015 Paris, France.
Gouin-Thibault I; INSERM, CIC 1414 (Centre d'Investigation Clinique de Rennes), Université de Rennes, CHU de Rennes, F-35000 Rennes, France.; CHU de Rennes, Department of Biological Hematology, F-35000 Rennes, France.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Feb 19; Vol. 21 (4). Date of Electronic Publication: 2020 Feb 19.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Blood Platelets/*metabolism
Inflammation/*metabolism
Neoplasms/*metabolism
Purinergic P2Y Receptor Antagonists/*pharmacology
Receptors, Purinergic P2Y12/*metabolism
Sepsis/*metabolism
Thrombosis/*metabolism
Acute Lung Injury/drug therapy ; Acute Lung Injury/metabolism ; Animals ; Anti-Inflammatory Agents/pharmacology ; Asthma/drug therapy ; Asthma/metabolism ; Atherosclerosis/diet therapy ; Atherosclerosis/genetics ; Atherosclerosis/immunology ; Atherosclerosis/metabolism ; Blood Platelets/drug effects ; Cytokines/metabolism ; Humans ; Inflammation/drug therapy ; Inflammation/immunology ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neoplasms/pathology ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Receptors, Purinergic P2Y12/chemistry ; Receptors, Purinergic P2Y12/genetics ; Sepsis/drug therapy ; Sepsis/immunology ; Sepsis/physiopathology ; Signal Transduction/drug effects ; Signal Transduction/genetics ; Thrombosis/drug therapy
Czasopismo naukowe
Tytuł :
What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?
Autorzy :
Cohen MV; Department of Physiology and Cell Biology, University of South Alabama College of Medicine, Mobile, AL, USA.; Department of Medicine, University of South Alabama College of Medicine, Mobile, AL, USA.
Downey JM; Department of Physiology and Cell Biology, University of South Alabama College of Medicine, Mobile, AL, USA.
Pokaż więcej
Źródło :
Journal of cardiovascular pharmacology and therapeutics [J Cardiovasc Pharmacol Ther] 2020 Mar; Vol. 25 (2), pp. 121-130. Date of Electronic Publication: 2019 Oct 23.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Coronary Artery Bypass*
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/instrumentation
Acute Coronary Syndrome/*therapy
Blood Platelets/*drug effects
Platelet Aggregation/*drug effects
Platelet Aggregation Inhibitors/*administration & dosage
Purinergic P2Y Receptor Antagonists/*administration & dosage
Receptors, Purinergic P2Y12/*drug effects
Acute Coronary Syndrome/blood ; Acute Coronary Syndrome/diagnosis ; Blood Platelets/metabolism ; Drug Administration Schedule ; Hemorrhage/chemically induced ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Purinergic P2Y Receptor Antagonists/adverse effects ; Receptors, Purinergic P2Y12/blood ; Risk Factors ; Signal Transduction ; Stents ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention.
Autorzy :
Luo L; Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China.
Fu M; Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Li Y; Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chen Z; Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yu J; Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Luo J; Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hu S; Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China.
Tu L; Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China.
Xu X; Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China.
Pokaż więcej
Źródło :
Clinical cardiology [Clin Cardiol] 2020 Mar; Vol. 43 (3), pp. 235-241. Date of Electronic Publication: 2019 Nov 28.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/instrumentation
Percutaneous Coronary Intervention*/mortality
Blood Platelets/*drug effects
Coronary Artery Disease/*therapy
Platelet Aggregation Inhibitors/*therapeutic use
Purinergic P2Y Receptor Antagonists/*therapeutic use
Receptors, Purinergic P2Y12/*drug effects
Aged ; Blood Platelets/metabolism ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/mortality ; Coronary Thrombosis/mortality ; Coronary Thrombosis/prevention & control ; Female ; Hemorrhage/chemically induced ; Humans ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Myocardial Infarction/prevention & control ; Platelet Aggregation Inhibitors/adverse effects ; Purinergic P2Y Receptor Antagonists/adverse effects ; Randomized Controlled Trials as Topic ; Receptors, Purinergic P2Y12/blood ; Risk Assessment ; Risk Factors ; Stents ; Stroke/mortality ; Stroke/prevention & control ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption.
Autorzy :
Samardzic J; Departments of Cardiovascular Diseases.
Bozina N; Laboratory Diagnostics; and.
Skoric B; Departments of Cardiovascular Diseases.
Ganoci L; Laboratory Diagnostics; and.
Krpan M; Departments of Cardiovascular Diseases.
Petricevic M; Cardiac Surgery, School of Medicine, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia; and.
Pasalic M; Departments of Cardiovascular Diseases.
Bozina T; Department of Medical Chemistry, Biochemistry and Clinical Chemistry, School of Medicine, University of Zagreb, Zagreb, Croatia.
Pavasovic S; Departments of Cardiovascular Diseases.
Cikes M; Departments of Cardiovascular Diseases.
Milicic D; Departments of Cardiovascular Diseases.
Pokaż więcej
Źródło :
Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2020 Feb; Vol. 75 (2), pp. 174-179.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Pharmacogenomic Variants*
Acute Coronary Syndrome/*drug therapy
Blood Platelets/*drug effects
Clopidogrel/*administration & dosage
Gastrointestinal Absorption/*genetics
Platelet Aggregation/*drug effects
Platelet Aggregation Inhibitors/*administration & dosage
Purinergic P2Y Receptor Antagonists/*administration & dosage
Receptors, Purinergic P2Y12/*drug effects
ATP Binding Cassette Transporter, Subfamily B/genetics ; ATP Binding Cassette Transporter, Subfamily B/metabolism ; Acute Coronary Syndrome/blood ; Acute Coronary Syndrome/diagnosis ; Aged ; Blood Platelets/metabolism ; Clopidogrel/metabolism ; Drug Monitoring ; Female ; Humans ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/metabolism ; Purinergic P2Y Receptor Antagonists/metabolism ; Randomized Controlled Trials as Topic ; Receptors, Purinergic P2Y12/blood ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y 12 Receptor.
Autorzy :
Li X; Department of Pharmacology, School of Pharmacy, Jilin University, Fujin Road, Changchun, Jilin, 130021, China.; Department of Infectious Diseases, The first hospital of Jilin University, Changchun, Jilin, 130021, China.
Liu P; Department of Pharmacology, School of Pharmacy, Jilin University, Fujin Road, Changchun, Jilin, 130021, China.
Xu Z; Department of Pharmacology, School of Pharmacy, Jilin University, Fujin Road, Changchun, Jilin, 130021, China.
Sun D; College of Life Sciences, Jilin University, Qianjin Street, Changchun, Jilin, 130012, China.; Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, School of Pharmacy, Yantai University, Yantai, 264005, China.
Gu J; College of Life Sciences, Jilin University, Qianjin Street, Changchun, Jilin, 130012, China.
Miao Y; Department of Pharmacology, School of Pharmacy, Jilin University, Fujin Road, Changchun, Jilin, 130021, China.
Zhang J; Department of Pharmacology, School of Pharmacy, Jilin University, Fujin Road, Changchun, Jilin, 130021, China.
Cao X; Department of Pharmacology, School of Pharmacy, Jilin University, Fujin Road, Changchun, Jilin, 130021, China. .
Pokaż więcej
Źródło :
Cardiovascular drugs and therapy [Cardiovasc Drugs Ther] 2020 Feb; Vol. 34 (1), pp. 15-23.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Blood Coagulation/*drug effects
Blood Platelets/*drug effects
Fibrinolytic Agents/*pharmacology
Piperidines/*pharmacology
Platelet Aggregation/*drug effects
Platelet Aggregation Inhibitors/*pharmacology
Purinergic P2Y Receptor Antagonists/*pharmacology
Receptors, Purinergic P2Y12/*drug effects
Thiophenes/*pharmacology
Thrombosis/*prevention & control
Animals ; Blood Platelets/metabolism ; Carrageenan ; Clopidogrel/pharmacology ; Cyclic AMP/blood ; Disease Models, Animal ; Fibrinolytic Agents/toxicity ; Hemorrhage/chemically induced ; Male ; Mice ; Piperidines/toxicity ; Platelet Aggregation Inhibitors/toxicity ; Prasugrel Hydrochloride/pharmacology ; Purinergic P2Y Receptor Antagonists/toxicity ; Rats, Wistar ; Receptors, Purinergic P2Y12/blood ; Thiophenes/toxicity ; Thrombosis/blood ; Thrombosis/chemically induced
Czasopismo naukowe
Tytuł :
Microglial P2Y12 Receptor Regulates Seizure-Induced Neurogenesis and Immature Neuronal Projections.
Autorzy :
Mo M; Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.; Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854.
Eyo UB; Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854.; Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905.; Center for Brain Immunology and Glia, Department of Neuroscience, University of Virginia, Charlottesville, Virginia 22908.
Xie M; Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905.
Peng J; Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854.; Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905.
Bosco DB; Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905.
Umpierre AD; Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905.
Zhu X; Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Tian DS; Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Xu P; Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China, .
Wu LJ; Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854, .; Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905.; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, and.; Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905.
Pokaż więcej
Źródło :
The Journal of neuroscience : the official journal of the Society for Neuroscience [J Neurosci] 2019 Nov 20; Vol. 39 (47), pp. 9453-9464. Date of Electronic Publication: 2019 Oct 09.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Microglia/*metabolism
Neurogenesis/*physiology
Neurons/*metabolism
Receptors, Purinergic P2Y12/*biosynthesis
Seizures/*metabolism
Animals ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Microglia/immunology ; Neurons/immunology ; Receptors, Purinergic P2Y12/genetics ; Receptors, Purinergic P2Y12/immunology ; Seizures/genetics ; Seizures/immunology
Czasopismo naukowe
Tytuł :
Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer.
Autorzy :
Novak I; Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, 2100 Copenhagen Ø, Denmark.
Yu H; Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, 2100 Copenhagen Ø, Denmark.
Magni L; Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, 2100 Copenhagen Ø, Denmark.
Deshar G; Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, 2100 Copenhagen Ø, Denmark.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Nov 20; Vol. 21 (22). Date of Electronic Publication: 2020 Nov 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Pancreatic Ductal/*drug therapy
Gene Expression Regulation, Neoplastic/*drug effects
Pancreatic Neoplasms/*drug therapy
Signal Transduction/*genetics
5'-Nucleotidase/genetics ; 5'-Nucleotidase/immunology ; Animals ; Apyrase/genetics ; Apyrase/immunology ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/immunology ; Carcinoma, Pancreatic Ductal/pathology ; Clinical Trials as Topic ; GPI-Linked Proteins/genetics ; GPI-Linked Proteins/immunology ; Gene Expression Regulation, Neoplastic/immunology ; Humans ; Immunotherapy/methods ; Pancreas/drug effects ; Pancreas/immunology ; Pancreas/pathology ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/immunology ; Pancreatic Neoplasms/pathology ; Pancreatic Stellate Cells/drug effects ; Pancreatic Stellate Cells/immunology ; Pancreatic Stellate Cells/pathology ; Receptors, Adenosine A2/genetics ; Receptors, Adenosine A2/immunology ; Receptors, Purinergic P2X7/genetics ; Receptors, Purinergic P2X7/immunology ; Receptors, Purinergic P2Y12/genetics ; Receptors, Purinergic P2Y12/immunology ; Receptors, Purinergic P2Y2/genetics ; Receptors, Purinergic P2Y2/immunology ; Signal Transduction/immunology ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/genetics ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
Genotype-guided treatment of oral P2Y 12 inhibitors: where do we stand?
Autorzy :
Claassens DM; Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands.
Ten Berg JM; Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands.; Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands.
Pokaż więcej
Źródło :
Pharmacogenomics [Pharmacogenomics] 2020 Jan; Vol. 21 (2), pp. 83-86.
Typ publikacji :
Editorial
MeSH Terms :
Acute Coronary Syndrome/*genetics
Cytochrome P-450 CYP2C19/*genetics
Purinergic P2Y Receptor Antagonists/*therapeutic use
Receptors, Purinergic P2Y12/*drug effects
Acute Coronary Syndrome/drug therapy ; Genotype ; Humans ; Percutaneous Coronary Intervention ; Platelet Aggregation Inhibitors/therapeutic use ; Receptors, Purinergic P2Y12/genetics
Opinia redakcyjna
Tytuł :
Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
Autorzy :
Wernly B; Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University, Salzburg, Austria.
Rezar R; Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University, Salzburg, Austria.
Gurbel P; Inova Center for Thrombosis Research and Translational Medicine, Falls Church, VA, USA.
Jung C; Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University of Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany. .
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2020 Jan; Vol. 49 (1), pp. 173-176.
Typ publikacji :
Comparative Study; Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Hemorrhage*/mortality
Hemorrhage*/prevention & control
Myocardial Infarction*/mortality
Myocardial Infarction*/therapy
Percutaneous Coronary Intervention*
Receptors, Purinergic P2Y12*
Aspirin/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Purinergic P2Y Receptor Antagonists/*therapeutic use
Female ; Humans ; Male
Czasopismo naukowe
Tytuł :
Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment.
Autorzy :
van Wageningen TA; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam, The Netherlands.
Vlaar E; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam, The Netherlands.; Present Address: Erasmus MC, Erasmus University Rotterdam, Center of lysosomal and metabolic diseases, Dept. Pediatrics and Clinical Genetics, Rotterdam, The Netherlands.
Kooij G; Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. Molecular Cell Biology and Immunology, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam, The Netherlands.
Jongenelen CAM; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam, The Netherlands.
Geurts JJG; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam, The Netherlands.
van Dam AM; Amsterdam UMC, location VUmc, Department of Anatomy and Neurosciences, De Boelelaan, 1108, 1081 HZ, Amsterdam, The Netherlands. .
Pokaż więcej
Źródło :
Acta neuropathologica communications [Acta Neuropathol Commun] 2019 Dec 11; Vol. 7 (1), pp. 206. Date of Electronic Publication: 2019 Dec 11.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gray Matter/*metabolism
Membrane Proteins/*metabolism
Microglia/*metabolism
Multiple Sclerosis/*metabolism
Receptors, Purinergic P2Y12/*metabolism
White Matter/*metabolism
Adult ; Aged ; Aged, 80 and over ; Female ; Gray Matter/chemistry ; Gray Matter/pathology ; Humans ; Inflammation/metabolism ; Inflammation/pathology ; Male ; Membrane Proteins/analysis ; Microglia/chemistry ; Microglia/pathology ; Middle Aged ; Multiple Sclerosis/pathology ; Receptors, Purinergic P2Y12/analysis ; White Matter/chemistry ; White Matter/pathology
Czasopismo naukowe
Tytuł :
Spatiotemporal analysis of impaired microglia process movement at sites of secondary neurodegeneration post-stroke.
Autorzy :
Kluge MG; School of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, Newcastle, NSW, Australia.
Abdolhoseini M; School of Electrical Engineering and Computer Science, University of Newcastle, Callaghan, NSW, Australia.
Zalewska K; School of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, Newcastle, NSW, Australia.
Ong LK; School of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, Newcastle, NSW, Australia.; NHMRC Centre of Research Excellence Stroke Rehabilitation and Brain Recovery, Heidelberg, VIC, Australia.
Johnson SJ; School of Electrical Engineering and Computer Science, University of Newcastle, Callaghan, NSW, Australia.
Nilsson M; Hunter Medical Research Institute, Newcastle, NSW, Australia.; NHMRC Centre of Research Excellence Stroke Rehabilitation and Brain Recovery, Heidelberg, VIC, Australia.
Walker FR; School of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, University of Newcastle, Callaghan, NSW, Australia.; Hunter Medical Research Institute, Newcastle, NSW, Australia.; NHMRC Centre of Research Excellence Stroke Rehabilitation and Brain Recovery, Heidelberg, VIC, Australia.
Pokaż więcej
Źródło :
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism [J Cereb Blood Flow Metab] 2019 Dec; Vol. 39 (12), pp. 2456-2470. Date of Electronic Publication: 2018 Sep 11.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Microglia/*metabolism
Neurodegenerative Diseases/*metabolism
Receptors, Purinergic P2Y12/*metabolism
Stroke/*metabolism
Thalamus/*metabolism
Animals ; Mice ; Mice, Transgenic ; Microglia/pathology ; Neurodegenerative Diseases/etiology ; Neurodegenerative Diseases/genetics ; Neurodegenerative Diseases/pathology ; Receptors, Purinergic P2Y12/genetics ; Stroke/complications ; Stroke/genetics ; Stroke/pathology ; Thalamus/pathology ; Time Factors
Czasopismo naukowe
Tytuł :
Preprocedural P2Y 12 inhibition and decrease in platelet count following transcatheter aortic valve replacement.
Autorzy :
Ibrahim H; Cardiothoracic Surgery and Cardiology Divisions, New York University School of Medicine, New York, New York.
Vapheas E; Cardiothoracic Surgery and Cardiology Divisions, New York University School of Medicine, New York, New York.
Shah B; Cardiothoracic Surgery and Cardiology Divisions, New York University School of Medicine, New York, New York.; VA New York Harbor Healthcare System, Manhattan Campus, New York, New York.
AlKhalil A; Rutgers University School of Medicine, Newark, New Jersey.
Querijero M; Cardiothoracic Surgery and Cardiology Divisions, New York University School of Medicine, New York, New York.
Jilaihawi H; Cardiothoracic Surgery and Cardiology Divisions, New York University School of Medicine, New York, New York.
Neuburger P; Cardiothoracic Surgery and Cardiology Divisions, New York University School of Medicine, New York, New York.
Staniloae C; Cardiothoracic Surgery and Cardiology Divisions, New York University School of Medicine, New York, New York.
Williams MR; Cardiothoracic Surgery and Cardiology Divisions, New York University School of Medicine, New York, New York.
Pokaż więcej
Źródło :
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2019 Nov 15; Vol. 94 (6), pp. 812-817. Date of Electronic Publication: 2019 May 06.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Blood Platelets/*drug effects
Clopidogrel/*administration & dosage
Purinergic P2Y Receptor Antagonists/*administration & dosage
Receptors, Purinergic P2Y12/*drug effects
Thrombocytopenia/*prevention & control
Transcatheter Aortic Valve Replacement/*adverse effects
Aged ; Aged, 80 and over ; Blood Platelets/metabolism ; Clopidogrel/adverse effects ; Female ; Humans ; Male ; Platelet Count ; Purinergic P2Y Receptor Antagonists/adverse effects ; Receptors, Purinergic P2Y12/blood ; Registries ; Retrospective Studies ; Risk Factors ; Thrombocytopenia/blood ; Thrombocytopenia/diagnosis ; Thrombocytopenia/etiology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention: Findings From the ADAPT-DES Study.
Autorzy :
Gupta R; University of Toledo Medical Center, OH (R.G.).
Kirtane AJ; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (A.J.K., Y.L., A.C., G.W., R.M., O.B.-Y., G.W.S.).; NewYork-Presbyterian Hospital/Columbia University Medical Center (A.J.K., O.B.-Y.).
Liu Y; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (A.J.K., Y.L., A.C., G.W., R.M., O.B.-Y., G.W.S.).
Crowley A; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (A.J.K., Y.L., A.C., G.W., R.M., O.B.-Y., G.W.S.).
Witzenbichler B; Helios Amper-Klinikum, Dachau, Germany (B.W.).
Rinaldi MJ; Sanger Heart and Vascular Institute/Atrium Health, Charlotte, NC (M.J.R.).
Metzger DC; Ballad Health CVA Heart Institute, Kingsport, TN (D.C.M.).
Weisz G; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (A.J.K., Y.L., A.C., G.W., R.M., O.B.-Y., G.W.S.).; Montefiore Medical Center, Bronx, NY (G.W.).
Stuckey TD; LeBauer-Brodie Center for Cardiovascular Research and Education/Cone Health, Greensboro, NC (T.D.S., B.R.B.).
Brodie BR; LeBauer-Brodie Center for Cardiovascular Research and Education/Cone Health, Greensboro, NC (T.D.S., B.R.B.).
Mehran R; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (A.J.K., Y.L., A.C., G.W., R.M., O.B.-Y., G.W.S.).; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.M., G.W.S.).
Ben-Yehuda O; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (A.J.K., Y.L., A.C., G.W., R.M., O.B.-Y., G.W.S.).; NewYork-Presbyterian Hospital/Columbia University Medical Center (A.J.K., O.B.-Y.).
Stone GW; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (A.J.K., Y.L., A.C., G.W., R.M., O.B.-Y., G.W.S.).; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.M., G.W.S.).
Pokaż więcej
Źródło :
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2019 Nov; Vol. 12 (11), pp. e007982. Date of Electronic Publication: 2019 Nov 01.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/instrumentation
Blood Platelets/*drug effects
Coronary Artery Disease/*therapy
Coronary Thrombosis/*prevention & control
Platelet Activation/*drug effects
Platelet Aggregation Inhibitors/*administration & dosage
Purinergic P2Y Receptor Antagonists/*administration & dosage
Receptors, Purinergic P2Y12/*drug effects
Smoking/*adverse effects
Aged ; Blood Platelets/metabolism ; Coronary Artery Disease/blood ; Coronary Artery Disease/diagnostic imaging ; Coronary Thrombosis/blood ; Coronary Thrombosis/etiology ; Drug-Eluting Stents ; Female ; Humans ; Male ; Middle Aged ; Non-Smokers ; Platelet Aggregation Inhibitors/adverse effects ; Prospective Studies ; Purinergic P2Y Receptor Antagonists/adverse effects ; Receptors, Purinergic P2Y12/blood ; Registries ; Risk Factors ; Smokers ; Smoking/blood ; Time Factors ; Treatment Outcome ; United States
Czasopismo naukowe
Tytuł :
Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.
Autorzy :
Lattuca B; Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).; Cardiology Department, Caremeau University Hospital, ACTION Study Group, Montpellier University, Nîmes, France (B.L., G.C.).
Silvain J; Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).
Yan Y; Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, China (Y.Y.).
Pouillot C; Cardiology Department, Sainte Clotilde Clinic, St. Denis de la Réunion, France (C.P.).
Cuisset T; ACTION Study Group, Cardiology Department, La Timone Hospital, Marseille, France (T.C.).
Cayla G; Cardiology Department, Caremeau University Hospital, ACTION Study Group, Montpellier University, Nîmes, France (B.L., G.C.).
Henry P; Cardiology Department (P.H.), Lariboisière University Hospital, Paris, France.
Diallo A; ACTION Study Group, Epidemiology and Clinic Research Unit (A.D., E.V.), Lariboisière University Hospital, Paris, France.
Elhadad S; Cardiology department, Lagny-Marne la Vallée Hospital, France (S.E.).
Rangé G; Cardiology department, Chartres Hospital, Le Coudray, France (G.R.).
Lhermusier T; Cardiology Department, Rangueil University Hospital, Toulouse, France (T.L., D.C.).
Boueri Z; Cardiology Department, Bastia Hospital, France (Z.B.).
Motreff P; Cardiology Department, Gabriel Montpied University Hospital, Clermont-Ferrand, France (P.M.).
Carrié D; Cardiology Department, Rangueil University Hospital, Toulouse, France (T.L., D.C.).
Vicaut E; ACTION Study Group, Epidemiology and Clinic Research Unit (A.D., E.V.), Lariboisière University Hospital, Paris, France.
Montalescot G; Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).
Collet JP; Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).
Pokaż więcej
Źródło :
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2019 Nov; Vol. 12 (11), pp. e007749. Date of Electronic Publication: 2019 Nov 07.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/instrumentation
Percutaneous Coronary Intervention*/mortality
Platelet Function Tests*
Blood Platelets/*drug effects
Drug Monitoring/*methods
Platelet Activation/*drug effects
Platelet Aggregation Inhibitors/*administration & dosage
Purinergic P2Y Receptor Antagonists/*administration & dosage
Receptors, Purinergic P2Y12/*drug effects
Aged ; Blood Platelets/metabolism ; Clinical Decision-Making ; Coronary Thrombosis/blood ; Coronary Thrombosis/etiology ; Coronary Thrombosis/prevention & control ; Drug-Eluting Stents ; Female ; Hemorrhage/chemically induced ; Humans ; Male ; Middle Aged ; Myocardial Infarction/blood ; Myocardial Infarction/etiology ; Myocardial Infarction/prevention & control ; Platelet Aggregation Inhibitors/adverse effects ; Predictive Value of Tests ; Purinergic P2Y Receptor Antagonists/adverse effects ; Receptors, Purinergic P2Y12/blood ; Risk Assessment ; Risk Factors ; Stroke/blood ; Stroke/etiology ; Stroke/prevention & control ; Time Factors ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies